Lutz Jermutus Selected Research

cotadutide

5/2024	Safety and Efficacy of Novel Incretin Co-agonist Cotadutide in Biopsy-proven Non-cirrhotic MASH with Fibrosis.
4/2024	Dual glucagon-like peptide-1 and glucagon receptor agonism reduces energy intake in type 2 diabetes with obesity.
12/2023	Cotadutide promotes glycogenolysis in people with overweight or obesity diagnosed with type 2 diabetes.
12/2022	Erratum. Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study. Diabetes Care 2021;44:1433-1442.
1/2022	Efficacy and safety of cotadutide, a dual glucagon-like peptide-1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney disease.
1/2021	Pharmacokinetics, safety, tolerability and efficacy of cotadutide, a glucagon-like peptide-1 and glucagon receptor dual agonist, in phase 1 and 2 trials in overweight or obese participants of Asian descent with or without type 2 diabetes.
1/2021	Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study.
1/2020	Resolution of NASH and hepatic fibrosis by the GLP-1R/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesis.
10/2018	MEDI0382, a GLP-1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single-dose, healthy-subject, randomized, Phase 1 study.
1/2018	MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Lutz Jermutus Research Topics

Disease

12	Type 2 Diabetes Mellitus (MODY) 05/2024 - 01/2018
7	Body Weight (Weight, Body) 05/2024 - 01/2017
7	Obesity 05/2024 - 11/2019
5	Overweight 12/2023 - 01/2018
4	Fibrosis (Cirrhosis) 05/2024 - 01/2020
4	Weight Loss (Weight Reduction) 04/2024 - 01/2018
4	Chronic Renal Insufficiency 12/2023 - 10/2018
4	Neoplasms (Cancer) 01/2023 - 03/2013
2	Inflammation (Inflammations) 12/2023 - 01/2016
2	Alcoholic Fatty Liver 12/2023 - 10/2018
2	Infections 10/2018 - 07/2012
1	Cachexia 10/2022
1	Vomiting 01/2021
1	Liver Cirrhosis (Hepatic Cirrhosis) 01/2021
1	Nausea 01/2021
1	Non-alcoholic Fatty Liver Disease 01/2021
1	Fatty Liver 01/2020
1	Metabolic Diseases (Metabolic Disease) 11/2019
1	Stroke (Strokes) 01/2019
1	Myocardial Infarction 01/2019
1	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2019
1	Proteinuria 01/2019
1	Starvation 01/2018
1	Hypoglycemia (Reactive Hypoglycemia) 01/2018
1	Gastrointestinal Diseases (Functional Gastrointestinal Disorders) 01/2018
1	Kidney Diseases (Kidney Disease) 01/2017
1	Hyperglycemia 01/2017
1	Albuminuria 01/2017
1	Lung Neoplasms (Lung Cancer) 10/2016
1	Gout 01/2016
1	Pain (Aches) 01/2016
1	Anaphylaxis (Anaphylactic Shock) 01/2016
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 07/2015
1	Disease Progression 02/2014
1	Alzheimer Disease (Alzheimer's Disease) 01/2014
1	Nociceptive Pain 06/2013
1	Breast Neoplasms (Breast Cancer) 02/2013
1	Asthma (Bronchial Asthma) 05/2006
1	Rheumatoid Arthritis 09/2003
1	Autoimmune Diseases (Autoimmune Disease) 09/2003

Drug/Important Bio-Agent (IBA)

10	Glucagon-Like Peptide 1 (GLP 1)IBA 05/2024 - 01/2018
10	cotadutideIBA 05/2024 - 01/2018
7	Glucagon Receptors (Glucagon Receptor)IBA 04/2024 - 01/2018
4	Peptides (Polypeptides)IBA 05/2024 - 01/2014
4	Liraglutide FDA Link 12/2023 - 01/2017
4	LipidsIBA 12/2023 - 01/2017
4	Glucose (Dextrose)FDA LinkGeneric 01/2021 - 01/2017
2	Insulin (Novolin)FDA Link 01/2022 - 01/2021
2	Blood Glucose (Blood Sugar)IBA 01/2018 - 01/2017
2	AntibodiesIBA 10/2016 - 09/2003
2	Proteins (Proteins, Gene)FDA Link 07/2015 - 05/2006
1	Glucagon (Glukagon)FDA Link 05/2024
1	IncretinsIBA 05/2024
1	Monoclonal AntibodiesIBA 01/2023
1	Growth Differentiation Factor 15IBA 10/2022
1	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 01/2021
1	Metformin (Glucophage)FDA LinkGeneric 01/2021
1	Biomarkers (Surrogate Marker)IBA 01/2021
1	Collagen Type III (Type III Collagen)IBA 01/2021
1	Proglucagon (Glucagon Precursors)IBA 01/2021
1	GlycogenIBA 01/2020
1	obeticholic acidIBA 01/2020
1	Apelin ReceptorsIBA 11/2019
1	LigandsIBA 11/2019
1	ApelinIBA 11/2019
1	GTP-Binding Proteins (G-Protein)IBA 11/2019
1	omega-Chloroacetophenone (Mace)IBA 01/2019
1	Immunosuppressive Agents (Immunosuppressants)IBA 10/2018
1	Growth Hormone (Somatotropin)IBA 01/2018
1	GhrelinIBA 01/2018
1	Abatacept (Orencia)FDA Link 01/2017
1	Type II Tumor Necrosis Factor ReceptorsIBA 10/2016
1	Urate Oxidase (Uricase)IBA 01/2016
1	Uric Acid (Urate)IBA 01/2016
1	Single-Chain AntibodiesIBA 07/2015
1	Designed Ankyrin Repeat ProteinsIBA 07/2015
1	Cisplatin (Platino)FDA LinkGeneric 07/2015
1	Amyloid (Amyloid Fibrils)IBA 02/2014
1	EnzymesIBA 01/2014
1	Neprilysin (Neutral Endopeptidase)IBA 01/2014
1	Amyloid beta-PeptidesIBA 01/2014
1	Voltage-Gated Sodium ChannelsIBA 06/2013
1	MEDI3617IBA 03/2013
1	Angiopoietin-2IBA 03/2013
1	AntigensIBA 02/2013
1	Anti-Bacterial Agents (Antibiotics)IBA 07/2012

Therapy/Procedure

7	Therapeutics 01/2023 - 07/2012
1	Drug Therapy (Chemotherapy) 12/2023
1	Glycemic Control 01/2021
1	Immunotherapy 10/2016